FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1956430368> ?p ?o ?g. }

• W1956430368 abstract "Bortezomib and lenalidomide are increasingly used in patients with AL amyloidosis, but long term data on their use as primary therapy in AL amyloidosis are lacking while early mortality remains significant. Thus, we analyzed the long term outcomes of 85 consecutive unselected patients, which received primary therapy with bortezomib or lenalidomide and we prospectively evaluated a risk adapted strategy based on bortezomib/dexamethasone to reduce early mortality. Twenty‐six patients received full‐dose bortezomib/dexamethasone, 36 patients lenalidomide with oral cyclophosphamide and low‐dose dexamethasone and 23 patients received bortezomib/dexamethasone at a dose and schedule adjusted to the risk of early death. On intent to treat, 67% of patients achieved a hematologic response (24% hemCRs) and 34% an organ response; both were more frequent with bortezomib. An early death occurred in 20%: in 36% of those treated with full‐dose bortezomib/dexamethasone, in 22% of lenalidomide‐treated patients but only in 4.5% of patients treated with risk‐adapted bortezomib/dexamethasone. Activity of full vs. adjusted dose bortezomib/dexamethasone was similar; twice weekly vs. weekly administration of bortezomib also had similar activity. After a median follow up of 57 months, median survival is 47 months and is similar for patients treated with bortezomib vs. lenalidomide‐based regimens. However, risk adjusted‐bortezomib/dexamethasone was associated with improved 1‐year survival vs. full‐dose bortezomib/dexamethasone or lenalidomide‐based therapy (81% vs. 56% vs. 53%, respectively). In conclusion, risk‐adapted bortezomib/dexamethasone may reduce early mortality and preserve activity while long term follow up indicates that remissions obtained with lenalidomide or bortezomib may be durable, even without consolidation with alkylators.Am. J. Hematol. 90:E60–E65, 2015. © 2015 Wiley Periodicals, Inc." @default.
• W1956430368 created "2016-06-24" @default.
• W1956430368 creator A5004781025 @default.
• W1956430368 creator A5007150057 @default.
• W1956430368 creator A5007677915 @default.
• W1956430368 creator A5016159295 @default.
• W1956430368 creator A5024471527 @default.
• W1956430368 creator A5026152671 @default.
• W1956430368 creator A5026413164 @default.
• W1956430368 creator A5030924651 @default.
• W1956430368 creator A5037198813 @default.
• W1956430368 creator A5041407463 @default.
• W1956430368 creator A5083511911 @default.
• W1956430368 creator A5088691462 @default.
• W1956430368 creator A5091600816 @default.
• W1956430368 date "2015-03-09" @default.
• W1956430368 modified "2023-09-27" @default.
• W1956430368 title "Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies" @default.
• W1956430368 cites W1701258200 @default.
• W1956430368 cites W1968646226 @default.
• W1956430368 cites W1969551915 @default.
• W1956430368 cites W1971828262 @default.
• W1956430368 cites W1973423645 @default.
• W1956430368 cites W1973853538 @default.
• W1956430368 cites W2001594121 @default.
• W1956430368 cites W2003181078 @default.
• W1956430368 cites W2008608243 @default.
• W1956430368 cites W2012680794 @default.
• W1956430368 cites W2013789617 @default.
• W1956430368 cites W2017612047 @default.
• W1956430368 cites W2022862731 @default.
• W1956430368 cites W2026585322 @default.
• W1956430368 cites W2027076242 @default.
• W1956430368 cites W2033793452 @default.
• W1956430368 cites W2036590404 @default.
• W1956430368 cites W2037825770 @default.
• W1956430368 cites W2039282816 @default.
• W1956430368 cites W2039607042 @default.
• W1956430368 cites W2041167176 @default.
• W1956430368 cites W2054091101 @default.
• W1956430368 cites W2058789242 @default.
• W1956430368 cites W2066276567 @default.
• W1956430368 cites W2070335603 @default.
• W1956430368 cites W2075174733 @default.
• W1956430368 cites W2077918440 @default.
• W1956430368 cites W2092074428 @default.
• W1956430368 cites W2092679212 @default.
• W1956430368 cites W2098093182 @default.
• W1956430368 cites W2107403553 @default.
• W1956430368 cites W2111080788 @default.
• W1956430368 cites W2113366568 @default.
• W1956430368 cites W2118848299 @default.
• W1956430368 cites W2128536827 @default.
• W1956430368 cites W2129528847 @default.
• W1956430368 cites W2143496573 @default.
• W1956430368 cites W2144506100 @default.
• W1956430368 cites W2151246487 @default.
• W1956430368 cites W2161231801 @default.
• W1956430368 cites W2163260428 @default.
• W1956430368 cites W2171033052 @default.
• W1956430368 cites W2171552949 @default.
• W1956430368 cites W2171783170 @default.
• W1956430368 cites W2415724568 @default.
• W1956430368 cites W4238487952 @default.
• W1956430368 doi "https://doi.org/10.1002/ajh.23936" @default.
• W1956430368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25580702" @default.
• W1956430368 hasPublicationYear "2015" @default.
• W1956430368 type Work @default.
• W1956430368 sameAs 1956430368 @default.
• W1956430368 citedByCount "52" @default.
• W1956430368 countsByYear W19564303682015 @default.
• W1956430368 countsByYear W19564303682016 @default.
• W1956430368 countsByYear W19564303682017 @default.
• W1956430368 countsByYear W19564303682018 @default.
• W1956430368 countsByYear W19564303682019 @default.
• W1956430368 countsByYear W19564303682020 @default.
• W1956430368 countsByYear W19564303682021 @default.
• W1956430368 countsByYear W19564303682022 @default.
• W1956430368 countsByYear W19564303682023 @default.
• W1956430368 crossrefType "journal-article" @default.
• W1956430368 hasAuthorship W1956430368A5004781025 @default.
• W1956430368 hasAuthorship W1956430368A5007150057 @default.
• W1956430368 hasAuthorship W1956430368A5007677915 @default.
• W1956430368 hasAuthorship W1956430368A5016159295 @default.
• W1956430368 hasAuthorship W1956430368A5024471527 @default.
• W1956430368 hasAuthorship W1956430368A5026152671 @default.
• W1956430368 hasAuthorship W1956430368A5026413164 @default.
• W1956430368 hasAuthorship W1956430368A5030924651 @default.
• W1956430368 hasAuthorship W1956430368A5037198813 @default.
• W1956430368 hasAuthorship W1956430368A5041407463 @default.
• W1956430368 hasAuthorship W1956430368A5083511911 @default.
• W1956430368 hasAuthorship W1956430368A5088691462 @default.
• W1956430368 hasAuthorship W1956430368A5091600816 @default.
• W1956430368 hasBestOaLocation W19564303681 @default.
• W1956430368 hasConcept C126322002 @default.
• W1956430368 hasConcept C141071460 @default.
• W1956430368 hasConcept C143998085 @default.
• W1956430368 hasConcept C2776063141 @default.
• W1956430368 hasConcept C2776364478 @default.
• W1956430368 hasConcept C2777478702 @default.

• next